JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

Strona główna・Stock List・Essa Pharma Inc

Essa Pharma Inc

Closed

1.88

Buy Sell

Overview

Share price change

24h

Current

Min

1.84

Max

1.88

Key metrics
By Trading Economics
Income	2.2M -6.4M
EPS	-0.14
Employees	35
EBITDA	-2.2M -8.5M

Market Stats
By TradingEconomics
Market Cap	7.5M 83M
Previous open	1.88
Previous close	1.88

Technical Score

By Trading Central

Confidence

Bearish Evidence

1.7 / 1.72 Support & Resistance

Essa Pharma Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

5 sie 2025, 23:11 UTC

Earnings

Australia's REA Hikes Dividend as Annual Profit Rises 23% -- Update

5 sie 2025, 22:45 UTC

Earnings

Australia's REA Hikes Dividend as Annual Profit Rises 23%

5 sie 2025, 22:39 UTC

Earnings

Great-West Lifeco Logs Lower 2Q Profit

5 sie 2025, 21:32 UTC

Earnings

Coupang Posts Higher 2Q Sales Due to Customer Growth

6 sie 2025, 00:00 UTC

Acquisitions, Mergers, Takeovers

NFL to Take 10% Stake in Disney's ESPN -- WSJ

6 sie 2025, 00:00 UTC

Acquisitions, Mergers, Takeovers

The NFL Is Taking a 10% Stake in Disney's ESPN -- WSJ

6 sie 2025, 00:00 UTC

Acquisitions, Mergers, Takeovers

Disney to Take Control of NFL Network as Part of Agreement -- WSJ

6 sie 2025, 00:00 UTC

Acquisitions, Mergers, Takeovers

Disney, NFL Strike Wide-Reaching Media-Asset Deal -- WSJ

5 sie 2025, 23:48 UTC

Market Talk

Nikkei May Decline Amid U.S. Economic Uncertainty -- Market Talk

5 sie 2025, 23:40 UTC

Market Talk

Gold Edges Higher, Supported by Fed Rate-Cut Hopes -- Market Talk

5 sie 2025, 23:19 UTC

Market Talk

Lindian Deal With Iluka Demonstrates Kangankunde Project Appeal -- Market Talk

5 sie 2025, 23:03 UTC

Market Talk

Earnings

Advanced Micro Devices' Data-Center Story Seen as Promising -- Market Talk

5 sie 2025, 22:22 UTC

Earnings

REA: Expectation of More Interest-Rate Cuts Likely to Support Buyer Demand>REA.AU

5 sie 2025, 22:21 UTC

Earnings

REA Expects FY26 Listing Volumes Broadly Flat on FY25>REA.AU

5 sie 2025, 22:20 UTC

Earnings

REA Expects September-Quarter Listings to Be Down on Year>REA.AU

5 sie 2025, 22:18 UTC

Earnings

REA July 2025 New Residential Listings Down 8% on Year>REA.AU

5 sie 2025, 22:17 UTC

Earnings

REA FY25 Australian Residential Listings Up 1% on Year>REA.AU

5 sie 2025, 22:17 UTC

Earnings

REA FY25 India Revenue A$129M Vs. A$103M>REA.AU

5 sie 2025, 22:16 UTC

Earnings

REA FY25 Core Australia Revenue A$1.54B Vs. A$1.35B>REA.AU

5 sie 2025, 22:16 UTC

Earnings

REA FY25 Core Operations Net Profit A$564.4M Vs. A$460.5M>REA.AU

5 sie 2025, 22:15 UTC

Earnings

REA Group FY25 Ebitda A$969.2M Vs. A$824.8M>REA.AU

5 sie 2025, 22:13 UTC

Earnings

REA Group Raises Dividend to A$1.38 Vs. A$1.02 >REA.AU

5 sie 2025, 22:13 UTC

Earnings

REA Group FY25 Rev A$1.67B Vs. A$1.45B >REA.AU

5 sie 2025, 22:12 UTC

Earnings

REA FY25 Core Operations Net Profit A$564.4M Vs, A$460.5M>REA.AU

5 sie 2025, 22:12 UTC

Earnings

REA Group FY25 Net A$677.9M Vs. Net A$302.8M >REA.AU

5 sie 2025, 21:58 UTC

Earnings

Novo Nordisk's Earnings Come After a Dramatic Guidance Cut. What to Look for Now. -- Barrons.com

5 sie 2025, 21:30 UTC

Earnings

AMD Gives a Strong Outlook. Why the Stock Is Falling. -- Barrons.com

5 sie 2025, 21:26 UTC

Earnings

AMD CEO Expects Embedded Segment to Return to Sequential Growth in Back Half of 2025

5 sie 2025, 21:23 UTC

Earnings

AMD CEO Sees Strong Customer Interest in MI400 Series for Large-Scale Deployments

5 sie 2025, 21:17 UTC

Earnings

AMD Expects Steep Production Ramp for MI350 Series in Back Half of Year, CEO Says

Peer Comparison

Price change

Essa Pharma Inc Forecast

Rating Consensus

By TipRanks

0 ratings

Buy

Hold

Sell

Based on 0 analysts giving stock ratings to Essa Pharma Inc - Dist in the past 3 months.

Technical Score

By Trading Central

1.7 / 1.72Support & Resistance

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Essa Pharma Inc

ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer. It has collaboration agreements with Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.